$2.31 2.5%
ABOS Stock Price vs. AI Score
Data gathered: November 21

AI Score



Sign up to see AI score

Brand Score Sign up
Employment Score Sign up
User Growth Score Sign up
Fundamental Score Sign up

AI Stock Analysis - Acumen Pharmaceuticals (ABOS)

Analysis generated October 29, 2024. Powered by Chat GPT.

Acumen Pharmaceuticals is a biotechnology firm that focuses on the development and commercialization of therapeutics to address unmet medical needs. The company's strategy involves rigorous scientific and regulatory approaches, emphasizing innovative and evidence-based solutions. Despite the high potential in the biotech sector, companies like Acumen are subject to considerable financial risks and benefits related to their product pipeline, regulatory approvals, and market adoption.

Read full AI stock Analysis

Stock Alerts - Acumen Pharmaceuticals (ABOS)

company logo Acumen Pharmaceuticals | November 19
Price is up by 6.3% in the last 24h.
company logo Acumen Pharmaceuticals | November 18
Price is down by -5.8% in the last 24h.
company logo Acumen Pharmaceuticals | November 15
Price is down by -5.2% in the last 24h.
company logo Acumen Pharmaceuticals | November 13
Price is down by -5.1% in the last 24h.

About Acumen Pharmaceuticals

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease.


Acumen Pharmaceuticals
Price $2.31
Target Price Sign up
Volume 35,870
Market Cap $144M
Year Range $2.14 - $4.33
Dividend Yield 0%
Analyst Rating 100% buy
Industry Biotechnology

In the news


Financial performance View All

Revenue Cost of Revenue Gross Profit Net Income ebitda EPS
Q3 '24100,0005M-4.9M-30M00.000
Q2 '2404.8M-4.8M-21M-24M-0.340
Q1 '243M5.3M-2.3M-15M-18M-0.250
Q4 '2310M5.2M5M-16M-18M-0.280
Q3 '2304.9M-4.9M-13M-16M-0.240

Insider Transactions View All

Meisner Derek M filed to sell 108,867 shares at $3.5.
January 19 '24
OConnell Daniel Joseph filed to sell 502,485 shares at $3.5.
January 19 '24
Barton Russell filed to sell 96,867 shares at $3.7.
January 19 '24
Siemers Eric filed to sell 117,576 shares at $3.7.
January 19 '24
Zuga Matt filed to sell 211,445 shares at $3.7.
January 19 '24

What is the Market Cap of Acumen Pharmaceuticals?

The Market Cap of Acumen Pharmaceuticals is $144M.

What is the current stock price of Acumen Pharmaceuticals?

Currently, the price of one share of Acumen Pharmaceuticals stock is $2.31.

How can I analyze the ABOS stock price chart for investment decisions?

The ABOS stock price chart above provides a comprehensive visual representation of Acumen Pharmaceuticals' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Acumen Pharmaceuticals shares. Our platform offers an up-to-date ABOS stock price chart, along with technical data analysis and alternative data insights.

Does ABOS offer dividends to its shareholders?

As of our latest update, Acumen Pharmaceuticals (ABOS) does not offer dividends to its shareholders. Investors interested in Acumen Pharmaceuticals should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.

What are some of the similar stocks of Acumen Pharmaceuticals?

Some of the similar stocks of Acumen Pharmaceuticals are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.

.
The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.
About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.



App download

Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

© 2024 AltIndex. All rights reserved.